Aspira Womens Health (FRA:CUL) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Aspira Womens Health 3-Year Dividend Growth Rate?

Aspira Womens Health's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The historical rank and industry rank for Aspira Womens Health's 3-Year Dividend Growth Rate or its related term are showing as below:

FRA:CUL's 3-Year Dividend Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 10.9
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Aspira Womens Health's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Aspira Womens Health's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Aspira Womens Health's 3-Year Dividend Growth Rate

For the Diagnostics & Research subindustry, Aspira Womens Health's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's 3-Year Dividend Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's 3-Year Dividend Growth Rate falls into.

Aspira Womens Health 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Aspira Womens Health (FRA:CUL) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Aspira Womens Health's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.378
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Womens Health 3-Year Dividend Growth Rate Related Terms>

Aspira Womens Health (FRA:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines